 TXB4, a novel brain-shuttle antibody, has been engineered to improve its ability to cross the blood-brain barrier. This antibody has been found to be more effective than its predecessor, TXB2, at delivering therapeutics to the brain. Additionally, this antibody can be used to deliver multiple therapeutics to the brain simultaneously. This article was authored by Pavel Stoky, Yaroslav Zeri, Michael Odemichuk, and others.